

LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahcoc.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINCIC, Ph.D.  
NICHOLAS P. TRIANO, III  
WILLIAM P. DAVAIL

CHI SUK KIM  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
PETER C. LAURO \*  
DeANN FORAN SMITH\*\*

\* Admitted in NY only  
\*\* Admitted in MI only  
\*\*\* Passed the Patent Bar Examination

PATENT AGENTS  
MEGAN E. WILLIAMS, Ph.D.

TECHNICAL SPECIALISTS  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.\*\*\*  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
LAUREN C. FOSTER, D.Sc.  
EUIHOON LEE  
ERICK B. BERGLUND, Ph.D.  
LISA M. DIROCCO  
JENNIFER K. ROSENFELD  
JUDITH STONE-HULSLANDER, Ph.D.



November 8, 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/163,648  
*ANGIOTENSIN CONVERTING ENZYME HOMOLOG AND THERAPEUTIC AND DIAGNOSTIC  
USES THEREFOR*  
Inventor: Acton, S.L. et al.  
Filed: September 30, 1998  
Our Ref. No.: MNI-132CP

RECEIVED

NOV 15 2000

TECH CENTER 1600/2900

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. PTO Form 1449;
3. Full copies of references cited in PTO Form 1449;
4. A copy of the International Search Report; and
5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on:


Date

Amy E. Mandragouras, Reg. No. 36,207

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras  
Registration No. 36,207  
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re the application of: Acton, S.L. et al.

Serial No.: 09/163,648

Filed: September 30, 1998

For: *Angiotensin Converting Enzyme Homolog and  
Therapeutic and Diagnostic Uses Therefor*

Attorney Docket No.: MNI-132CP

Group Art Unit: 1653

Examiner: A. Gupta

RECEIVED

NOV 15 2000

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below

11/8/00  
Date of Signature and of Mail Deposit

By: 

Amy E. Mandragouras  
Registration No. 36,207  
Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney have become aware of the following publications and information, cited in an International Search Report mailed August 8, 2000 during the prosecution of PCT/US99/22976 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's


consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(1), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Amy E. Mandragouras  
Registration No. 36,207  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: 11/8/00

GAD/AEM/MCL/alf  
Enclosures

